読み込み中
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
通常取引
$37.9491
+$1.1191 · +3.04%
日中の時刻はETです。市場データは遅延する場合があります。
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
日中レンジ
現在 $37.9491
52週レンジ
現在 $37.9491
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
65
割安
センチメント
57
まちまち
リスク
40
中程度のリスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
日中レンジ
現在 $37.9491
52週レンジ
現在 $37.9491
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.1億 USD | 9039.8万 USD | 8271.3万 USD | 6435.7万 USD | 4804.2万 USD |
| 売上原価 | 1244.7万 USD | 888.1万 USD | 936.1万 USD | 765.4万 USD | 515.7万 USD |
| 粗利益 | 9734.1万 USD | 8151.7万 USD | 7335.2万 USD | 5670.3万 USD | 4288.5万 USD |
| 研究開発 | 6710.7万 USD | 5714.5万 USD | 4561.4万 USD | 5290.6万 USD | 4764.2万 USD |
| 販売・一般管理 | 1.55億 USD | — | 9327.4万 USD | 8283.8万 USD | — |
| 営業費用 | 2.22億 USD | 1.78億 USD | 1.39億 USD | 1.36億 USD | 1.35億 USD |
| 受取利息 | 596.5万 USD | 890.1万 USD | 264.1万 USD | 93.8万 USD | 36.5万 USD |
| 支払利息 | 3384.8万 USD | 1252.1万 USD | 1471.5万 USD | 843.8万 USD | 1744.4万 USD |
| 減価償却費と償却費 | 241.1万 USD | 118.6万 USD | 170.5万 USD | 181.7万 USD | 177.3万 USD |
| 営業利益 | −1.25億 USD | −9678.2万 USD | −6553.6万 USD | −7904.1万 USD | −9229.2万 USD |
| 純利益 | −1.53億 USD | −1.27億 USD | −1.02億 USD | −1.1億 USD | −1.11億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM4097.58万0.05%787.4億 USD0.19%$278.71-0.08%
iShares Russell 2000 Growth ETFIWO1250.05万0.09%139.17億 USD0.24%$355.22-0.44%
iShares Biotechnology ETFIBB1186.89万0.11%108.2億 USD0.44%$205.33-0.56%
Vanguard Russell 2000 ETFVTWO1054.67万0.06%180億 USD0.06%$112.58-0.08%
Fidelity Enhanced Small Cap ETFFESM782.88万0.12%64.1億 USD0.28%$45.43-0.07%
State Street SPDR Portfolio Developed World ex-US ETFSPDW695.7万0.02%404.62億 USD0.03%$49.795-0.36%
Vanguard Health Care ETFVHT510.31万0.02%220億 USD0.09%$319.74+0.23%
iShares Micro-Cap ETFIWC494.95万0.38%13.17億 USD0.60%$182.54-0.25%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
